Navigation Links
Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Date:3/6/2008

December 31,

2007 2006 2005 2007

$ $ $ $

-------------------------------------------------------------------------

Revenue

Rights revenue - - - 310,000

-------------------------------------------------------------------------

- - - 310,000

-------------------------------------------------------------------------

Expenses

Research and

development 11,315,088 10,535,689 9,308,977 54,536,282

Operating 3,987,688 3,630,144 3,083,372 20,758,269

Stock based

compensation 539,156 403,550 64,104 4,704,805

Foreign

exchange loss 8,862 35,270 253,608 657,710

Amortization

- intellectual

property 962,427 874,043 786,459 4,999,261

Amortization

- capital assets 40,714 52,637 69,532 448,397

-------------------------------------------------------------------------

16,853,935 15,531,333 13,566,052 86,104,724

-------------------------------------------------------------------------

Loss before the

following 16,853,935 15,531,333 13,566,052 85,794,724

Interest income (1,211,744) (1,233,809) (783,456) (6,014,749)

Gain on sale of

BCY LifeSciences

Inc. - - (765) (299,403)

Loss on sale of

Transition

Therapeutics

Inc. - - - 2,156,685

---------------------------------------------------------------------
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
3. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
4. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
5. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
6. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
8. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
9. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
10. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
11. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Researchers from the Southern University of ... back pain, and the acne causing P.acnes bacteria. Researchers believe ... bacteria seek out oxygen deprived location to seek shelter and ... P.acnes has the ability to live in the open joint ... spokesman for “ The best acne treatment ” explains why ...
(Date:5/20/2013)... WILMINGTON, Del. (PRWEB) May 20, 2013 ... named 14 young faculty members to its 2013 ... three years, the company will provide this outstanding ... their work in advancing basic science to meet ... is designed to help promising young and untenured ...
(Date:5/20/2013)... 2013 On 25-28 July, 2013, UPCP ... Paris - the beautiful city of lights. , According ... is revolutionizing the medical world. Understanding and integrating genetic ... hallmark of this transformation. Much of the present medical ... epidemiologic studies of large cohorts that do not take ...
(Date:5/20/2013)... Kitware, a leader in data visualization, today ... exploration of hospital costs across the United States ... recent release of “Medicare Provider Charge Data,” a dataset ... from the Centers for Medicare & Medicaid Services. , ... hospitals across the country has sparked considerable controversy; however, ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2Kitware Enables Interactive Exploration of CMS Medicare Data 2
... Corporation (NASDAQ: LIFE ) today announced it ... Conference on Tuesday, September 20 at 8:00am ET.  Greg ... present on behalf of the company. The company will ... weeks following the conference on the Life Technologies, investor ...
... Aug. 29, 2011 Chemical Abstracts Service ( CAS ... that Syngene International , an internationally reputed contract ... biotechnology company, has signed a three-year contract to provide ... award-winning chemistry research tool. SciFinder offers ...
... 26, 2011 Quantum Learning, Inc. (QLI), ... programs, and Jay Elliot, author of the book " ... announced today a licensing agreement.  Under the terms of ... training program called "Market-Leading Innovation™ (The path to Innovation ...
Cached Biology Technology:Life Technologies to Present at the UBS 2011 Global Life Sciences Conference 2Syngene Expands Ongoing Relationship with CAS to Provide SciFinder® to All Its Scientists 2Syngene Expands Ongoing Relationship with CAS to Provide SciFinder® to All Its Scientists 3Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way" 2Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way" 3
(Date:5/17/2013)... Rutgers, The State University of New Jersey, and City ... formulation called Visikol TM that effectively clears organisms ... in place of chloral hydrate, which is one of ... is tightly regulated by the Drug Enforcement Administration (DEA) ... solutions, or clearing agents, are vital for viewing organisms ...
(Date:5/17/2013)... antelope can live at elevations of 4,000-5,000m on ... in Nature Communications , investigators from Qinghai ... some genetic factors may be associated with the ... in this work will also provide implications for ... other ruminant species. , The Tibetan antelope ( ...
(Date:5/17/2013)... The Federation of American Societies for Experimental Biology ... Institutes of Health (NIH) funding trends highlighting the devastating ... critical research. The FASEB analysis follows a May 15th ... MD, PhD, who testified that the $1.6 billion cut ... is "having a substantial impact on the scientific community." ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... YORK (Dec. 19, 2007) -- Two deadly and highly infectious ... their match in a new drug developed by scientists at ... and Nipah viruses are related, newly recognized zoonotic viruses that ... larger animals -- including pigs, horses and humans. ...
... kiss you, I,ve got a cold,. But a report just published ... on an infection by shaking someone,s hand than in sharing a ... and the UK have published the first detailed report on hand ... healthcare settings. Their findings are published in the American Journal of ...
... is the first poll to reflect the discovery reported ... used to create stem cells or their near equivalents. ... than six in 10, or 63 percent, say that ... needed, 22 percent say this development means embryonic stem ...
Cached Biology News:Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports 2Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports 3If you don't want to fall ill this Christmas, then share a festive kiss but don't shake hands 2If you don't want to fall ill this Christmas, then share a festive kiss but don't shake hands 3Widespread support for nonembryonic stem cell research, VCU Life Sciences Survey shows 2
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Biology Products: